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Decreased Myocardial Injury and Improved Contractility After
Administration of a Peptide Derived Against the Alpha-Interacting
Domain of the L-Type Calcium Channel
Helena M. Viola, PhD; Maria C. Jordan, MD; Kenneth P. Roos, PhD; Livia C. Hool, PhD
Background-—Myocardial infarction remains the leading cause of morbidity and mortality associated with coronary artery disease.
The L-type calcium channel (ICa-L) is critical to excitation and contraction. Activation of the channel also alters mitochondrial
function. Here, we investigated whether application of a alpha-interacting domain/transactivator of transcription (AID-TAT) peptide,
which immobilizes the auxiliary b2 subunit of the channel and decreases metabolic demand, could alter mitochondrial function and
myocardial injury.
Methods and Results-—Treatment with AID-TAT peptide decreased ischemia-reperfusion injury in guinea-pig hearts ex vivo (n=11)
and in rats in vivo (n=9) assessed with uptake of nitroblue tetrazolium, release of creatine kinase, and lactate dehydrogenase.
Contractility (assessed with catheterization of the left ventricle) was improved after application of AID-TAT peptide in hearts ex vivo
(n=6) and in vivo (n=8) up to 12 weeks before sacrifice. In search of the mechanism for the effect, we found that intracellular
calcium ([Ca2+]i, Fura-2), superoxide production (dihydroethidium fluorescence), mitochondrial membrane potential (Ψm, JC-1
fluorescence), reduced nicotinamide adenine dinucleotide production, and flavoprotein oxidation (autofluorescence) are decreased
after application of AID-TAT peptide.
Conclusions-—Application of AID-TAT peptide significantly decreased infarct size and supported contractility up to 12 weeks
postcoronary artery occlusion as a result of a decrease in metabolic demand during reperfusion. ( J Am Heart Assoc. 2014;3:
e000961 doi: 10.1161/JAHA.114.000961)
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M inimizing myocardial damage and oxidative stress (OS)during reperfusion after ischemia is associated with a
decrease in morbidity and mortality.1 Reperfusion of the
ischemic heart during coronary occlusion remains the primary
objective to prevent further cardiac damage in the clinical
setting. However, the reperfusion period imposes deleterious
effects as a result of the generation of reactive oxygen
species (ROS) and increases in intracellular calcium ([Ca2+]i,
Fura-2) that contribute to development of cardiac hypertrophy
and cardiac failure.2,3 ROS produced as a result of rapid
changes in oxygen can influence the activity of ion channels.
The function of the L-type calcium channel (ICa-L) is altered
during changes in OS as a result of redox modification of the
channel protein by H2O2.
4–10 This leads to an increase in
protein synthesis and cell size consistent with the develop-
ment of myocyte hypertrophy.11,12 Increased calcium influx
through the channel is sufficient to induce cardiac hypertro-
phy in mice overexpressing the alpha subunit,13 and increased
expression of the b2 auxiliary subunit alters contractility and
leads to single-channel activity characteristic of heart fail-
ure.14,15 Therefore, ICa-L represents a viable target for
reduction of injury and prevention of remodeling after
ischemia-reperfusion (I/R).
ICa-L is a heterotetramer comprised of the a1, b2, and a2-d
subunits. The a1 subunit contains the pore-forming (S5-S6)
and voltage-sensing (S4) regions responsible for ion conduc-
tance. The b2 subunit binds to the a1 subunit at the alpha-
interacting domain (AID) and assists with the trafficking and
insertion of the a1 subunit in the cell membrane.
16 The b2
subunit also regulates inactivation of the current and couples
to cytoskeletal proteins.16–18 ICa-L is critical to cardiac
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excitation and contraction. Activation of the channel can also
alter mitochondrial function. Calcium influx through the
channel is sufficient to increase cytosolic calcium, mitochon-
drial calcium uptake, reduction of nicotinamide adenine
dinucleotide (NAD+) to reduced nicotinamide adenine dinu-
cleotide (NADH), superoxide production, and metabolic activ-
ity in a calcium-dependent manner.19 Activation of the
channel can also increase mitochondrial membrane potential
(MMP). The response is reversible upon inactivation of the
channel during voltage clamp and is mediated through the
movement of cytoskeletal proteins.19 Application of a peptide
derived against the AID of the channel using a transactivator
of transcription (TAT) sequence to facilitate transfer across
the membrane (AID-TAT peptide) attenuates the increase in
MMP and metabolic activity after activation of the channel.19
The peptide immobilizes the auxiliary b2 subunit and induces
functional uncoupling from the actin cytoskeleton.20 There-
fore, the channel can modulate mitochondrial function and
metabolic activity in cardiac myocytes.
In this study, we tested the efficacy of AID-TAT peptide in
reducing damage in hearts exposed to I/R injury ex vivo. We
demonstrate that the peptide significantly decreased infarct
size. In addition, contractility was improved within 30 minutes
after exposure to the peptide ex vivo and up to 12 weeks
post-CAL (coronary artery ligation) in rats in vivo. Superoxide
production, NADH, flavoprotein oxidation, and metabolic
activity were decreased after application of the peptide,
suggesting that the peptide “supported” myocardial metabo-
lism during the critical reperfusion period. Therefore, applica-
tion of the AID-TAT peptide may represent a viable therapy in
the prevention of myocardial damage and support of
contractile function post-MI (myocardial infarction).
Methods
Synthesis of Peptides
A peptide corresponding to the a1-b interaction domain in the
I-II linker of the a1C subunit was synthesized using the amino
acid sequence, QQLEEDLKGYLDWITQAE20 (Auspep Pty. Ltd.,
Parkville, VIC, Australia). The scrambled peptide control was
also synthesized (QKILGEWDLAQYTDQELE). A cell-penetrating
TAT sequence was tethered to the peptides with the amino
acids, RKKRRQRRR-(6-aminohexanoic acid).
Animal Models
In vitro studies
Freshly isolated myocytes from 8-week-old male C57BL mice
were used for all fluorescent studies.21,22 Animals were
anesthetized with intraperitoneal injection of pentobarbitone
sodium (240 mg/kg) before excision of the heart, as
approved by the animal ethics committee of The University
of Western Australia in accord with the Australian Code of
Practice for the Care and Use of Animals for Scientific
Purposes (NH&MRC, 8th Edition, 2013). A total number of 33
mice were used. All experiments were performed in Hepes-
buffered solution containing (in mmol/L) 5.3 KCl, 0.4
MgSO4.7H2O, 139 NaCl, 5.6 Na2HPO4.2H2O, 2.5 CaCl2, 5
glucose, 20 Hepes, and 2 glutamine (pH=7.4 at 37°C).
Ex vivo studies
Adult tricolor guinea pigs weighing 250 g were used for all
ex vivo infarct size and contractility studies. Animals were
anesthetized with intraperitoneal injection of pentobarbitone
sodium (240 mg/kg) before excision of the heart, as
approved by the animal ethics committee of The University
of Western Australia in accord with the Australian Code of
Practice for the Care and Use of Animals for Scientific
Purposes (NH&MRC, 8th Edition, 2013). A total number of 76
guinea pigs were used.
In vivo studies
Adult Fischer rats weighing 250 g were used for all in vivo
infarct size and contractility studies. Animals were anesthetized
with 50 mg/kg of sodium pentobarbital, as approved by The
UCLA Chancellor’s Office of Animal Research Oversight in
accord with the USPHS Policy and the Guide for the Care and
Use of Laboratory Animals. A total number of 46 rats were used.
Ischemia-Reperfusion
In vitro
Intact ventricular myocytes were exposed to 40 lmol/L of
H2O2 for 5 minutes, followed by 10 U/mL of catalase (CAT)
to degrade the H2O2, to mimic the effect of a transient OS in
vivo associated with I/R injury, as previously described.10
Ex vivo studies
Hearts excised from guinea pigs were perfused retrogradely
by a Langendorff apparatus. Hearts were exposed to
30 minutes of coronary perfusion with calcium-containing
Krebs-Henseleit buffer solution at 7 mL/min, followed by
30 minutes of no-flow ischemia and, finally, 30 minutes of
reperfusion. AID-TAT peptide or AID(S)-TAT peptide (1 or
10 lmol/L) was administered immediately upon reperfusion.
In vivo studies
MI was induced under aseptic conditions in Fischer rats with
ligation of the coronary artery for 30 minutes using methods
adapted from previous studies.23,24 Three minutes after
reperfusion, AID-TAT peptide or AID(S)-TAT peptide, or saline,
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was injected into the chamber of the left ventricle (LV) such
that the final circulating concentration of the peptide in the
blood of the rat was 1 or 10 lmol/L, the chest was closed,
and the rats were allowed to recover for up to 12 weeks.
Measurement of Intracellular Calcium
[Ca2+]i was monitored in myocytes using the fluorescent
indicator, Fura-2 AM (Fura-2, 1 lmol/L, excitation 340/
380 nm, emission 510 nm; Molecular Probes, Eugene, OR) at
37°C, as previously described.10 Fluorescence at 340/380-
nm excitation and 510-nm emission were measured at 1-
minute intervals with an exposure of 50 ms on a Hamamatsu
Orca ER digital camera (Hamamatsu Photonics, K.K., Ham-
amatsu City, Japan) attached to an inverted Nikon TE2000-U
microscope (Nikon Corporation, Tokyo, Japan). Ratiometric
340/380-nm signal of individual myocytes was quantified
using MetaMorph 6.3 (Molecular Devices, Sunnyvale, CA) to
measure signal intensity of manually traced cell regions. An
equivalent region not containing cells was used for back-
ground and was subtracted. Fluorescent ratios recorded over
3 minutes were averaged 2 minutes after incubation with
drugs and reported as a percentage change from the baseline
pretreatment average.
Measurement of Superoxide
Superoxide generation was assessed in myocytes using
fluorescent DHE (5 lmol/L, 515 to 560-nm excitation filter,
590-nm long-pass emission) at 37°C, as previously
described.10 Fluorescent signal was acquired at 1-minute
intervals with 200-ms exposure on a Hamamatsu Orca ER
digital camera (Hamamatsu Photonics, K.K.) attached to an
inverted Nikon TE2000-U microscope (Nikon Corporation).
MetaMorph 6.3 (Molecular Devices) was used to quantify the
signal by manually tracing myocytes. An equivalent region
not containing cells was used as background and was
subtracted. Fluorescence was reported as the slope of the
signal measured at 16 to 30 minutes (treatment) as a
percentage change from the slope measured at 1 to
15 minutes (basal).
Measurement of MMP (Ψm)
The fluorescent indicator, 5,50,6,60-tetrachloro-1,10,3,30-tetra-
ethylbenzimidazolylcarbocyanine iodide (JC-1; 200 nmol/L,
excitation 480 nm, emission 580/535 nm; Molecular
Probes), was used to measure Ψm at 37°C, as previously
described.10 Fluorescence at 480-nm excitation and 580/
535-nm emission signal were measured at 2-minute intervals
with an exposure of 50 ms on a Hamamatsu Orca ER digital
camera (Hamamatsu Photonics, K.K.) attached to an inverted
Nikon TE2000-U microscope (Nikon Corporation). Ratiometric
580/535-nm signal of individual myocytes were quantified
using MetaMorph 6.3 (Molecular Devices) to measure signal
intensity of manually traced myocytes. An equivalent region
not containing cells was used as background and was
subtracted. Fluorescent ratios recorded over 3 minutes
before and 7 minutes after addition of drugs were averaged
and alterations in fluorescent ratios reported as a percentage
increase from the basal average. To confirm that the JC-1
signal was indicative of Ψm, 4 mmol/L of sodium cyanide
(NaCN) was added at the end of each experiment to collapse
Ψm. In addition, individual 580- and 535-nm signals were
assessed in each experiment to confirm that the fluorescent
indicator was accurately measuring Ψm.
Measurement of Mitochondrial Flavoprotein
Oxidation
Flavoprotein autofluorescence was used to measure flavopro-
tein oxidation in myocytes at 37°C based on previously
described methods (excitation 480 nmol/L, emission
535 nm).25 Fluorescent images were taken at 1-minute
intervals with 1.5 seconds of exposure on a Hamamatsu
Orca ER digital camera (Hamamatsu Photonics, K.K.) attached
to an inverted Nikon TE2000-U microscope (Nikon Corpora-
tion). MetaMorph 6.3 (Molecular Devices) was used to
quantify the signal by manually tracing myocytes. An equiv-
alent region not containing cells was used as background and
was subtracted. Fluorescent values recorded over 5 minutes
before and 7 minutes after addition of drugs were averaged
and alterations in fluorescent ratios reported as percentage
increase from the basal average. FCCP (10 lmol/L) was
added at the end of each experiment to achieve a maximum
fluorescence value indicative of maximum flavoprotein
oxidation.
Measurement of Mitochondrial NADH
Autofluorescence of NADH was monitored in myocytes at
37°C, as previously described (excitation 365 nmol/L, emis-
sion 460/535 nm).12 Fluorescence at 365-nm exciation and
460/535-nm emission were measured at 1-minute intervals
with 1.5 seconds of exposure on a Hamamatsu Orca ER
digital camera (Hamamatsu Photonics, K.K.) attached to an
inverted Nikon TE2000-U microscope (Nikon Corporation).
Ratiometric 460/535-nm signal of individual myocytes were
quantified using MetaMorph 6.3 (Molecular Devices) to
measure signal intensity of manually traced myocytes. An
equivalent region not containing cells was used as back-
ground and was subtracted. Fluorescent ratios recorded over
3 minutes before and 7 minutes after treatments were
averaged and alterations in fluorescent ratio were reported
DOI: 10.1161/JAHA.114.000961 Journal of the American Heart Association 3
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as percentage increase from the baseline average. To confirm
that the NADH signal was indicative of mitochondrial NADH
production, 4 mM of sodium cyanide was added at the end of
each experiment to deplete mitochondria of NADH after
collapse of Ψm.
Creatine Kinase and Lactate Dehydrogenase
Assays
Creatine kinase (CK) and lactate dehydrogenase (LDH) levels
were determined from perfusate from ex vivo hearts before
and after ischemia, as previously described.4 CK activity was
determined using a Randox CK N-acetyl-L-cysteine-activated
diagnostic kit (Randox Laboratories Ltd., Crumlin, UK). The
rate of increase in absorbance was measured at 340 nm
(PowerWave XS; BioTek Instruments, Inc., Winooski, VT) over
15 minutes at 30°C. CK activity was calculated using the
following equation: CK activity (U/L)=41279D Abs 340 nm/
min. To determine LDH activity, 150 lL of perfusate was
mixed with 50 lL of LDH assay buffer (50 mmol/L of
imidazole, 375 lmol/L of NADH, 4 mmol/L of pyruvate,
and 0.05% BSA; pH 7.0) and the rate of decrease in
absorbance was measured at 340 nm (PowerWave XS;
BioTek) over 15 minutes at 25°C. LDH activity was calculated
using the following equation: LDH activity (U/mL)=([D Abs
340 nm/min TESTD Abs 340 nm/min BLANK][3][dilution
factor])/([6.22][0.1]).
Measurement of Infarct Size
Following ex vivo or in vivo I/R protocols, hearts were stained
with 0.1% nitroblue tetrazolium dye to assess infarct size.
Area of damage was quantitated using ImageJ software
(National Institutes of Health, Bethesda, MD) and reported as
percentage (%) of LV area.
Glutathione Assay
Reduced glutathione/oxidized glutathione (GSH/GSSG) ratio
was determined in ischemia-reperfused hearts based on
previously described methods.4,26 Tissue homogenates were
centrifuged at 80009g for 10 minutes at 4°C, and GSH/
GSSG ratio was measured from the supernatant. Fluores-
cence was detected using a spectrophotometer (PowerWave
XS; BioTek) at 412 nm.
Contractility Studies
Ex vivo
LV pressure (LVP) was assessed in guinea pig hearts
exposed to I/R by inserting a fluid-filled latex balloon
connected to a pressure transducer into the left ventricular
chamber. LVP measurements were recorded using a Power-
Lab data acquisition system and LabChart7 (ADInstruments,
Bella Vista, NSW, Australia). The balloon was inflated to an
end-diastolic pressure of 10 mm Hg, and the volume was
maintained throughout the experiment. Coronary perfusion
was maintained at 7 mL/min. LV developed pressure was
calculated as follows: max pressure (mm Hg)–min pressure
(mm Hg).
In vivo
Ventricular function was assessed at 12 weeks post-MI (end
of study) by catheterization of the LV with a 2.0-Fr catheter
(Millar Instruments, Houston, TX), as previously described.23
Rats were anesthetized with isoflurane, intubated, the chest
opened, and the Millar catheter inserted directly into the LV
through a 20-Ga angiocatheter. After stabilization, LVPs,
contractility, and relaxation (dP/dT) data were acquired and
analyzed with HEM V4.2 software (Notocord Systems, Croissy
sur Seine, France). All hemodynamic data were recorded
continuously for at least 30 minutes to ensure physiological
levels of pressures and heart rates. For the peptide control
study without an infarct, a femoral artery was also catheter-
ized for pressure recording and peptide infusion. At the end of
the functional evaluation, the rat was euthanized with an
overdose of anesthetic, the hearts removed, weighed, and
stained for infarct size.
Statistical Analysis
Results are reported as meanSEM. Statistical comparisons
of responses between unpaired data were made using the
Student’s t-test or between groups of cells using 1-way
ANOVA and Tukey’s post-hoc test. Where sample sizes were
small and did not fit a Gaussian distribution, we used
the nonparametric Kruskal-Wallis test, followed by Dunn’s
multiple comparison test to identify the significant data
(GraphPad Prism version 3.02; GraphPad Software, Inc., La
Jolla, CA).
Results
AID-TAT Peptide Decreases I/R Injury in Hearts
Ex Vivo
We examined the effect of a single application of 1 lmol/L of
AID-TAT peptide injected into the coronaries through the aorta
within 5 minutes after commencement of reperfusion in
hearts exposed to 30 minutes of no-flow ischemia on a
Langendorff apparatus. In hearts exposed to active peptide,
infarct size was significantly decreased, compared to hearts
exposed to 1 lmol/L of scrambled peptide (AID(S)-TAT)
(Figure 1A and 1B). Release of CK (Figure 1C) and LDH
DOI: 10.1161/JAHA.114.000961 Journal of the American Heart Association 4
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(Figure 1D) was significantly less in hearts exposed to active
peptide. However, the ratio of GSH/GSSG was not altered
after administration of 1 lmol/L of AID-TAT. When the
concentration of the active peptide was increased to
10 lmol/L, GSH increased, suggesting an attenuation of OS
(Figure 1E).
A B
C
E
D
Figure 1. AID-TAT peptide decreases ischemia-reperfusion (I/R) injury in hearts ex vivo. A, Representative sections from guinea pig hearts
after I/R treated with 1 lmol/L of scrambled (AID(S)-TAT) or active (AID-TAT) peptides. Infarct size is assessed as area that did not take up
nitroblue tetrazolium dye. B, MeanSEM of infarct size expressed as percentage (%) of total left ventricular (LV) area for all hearts treated with
AID(S)-TAT or AID-TAT as indicated. C, Creatine kinase (CK) activity of hearts treated with 1 lmol/L of scrambled (AID(S)-TAT) or active (AID-
TAT) peptides before (Pre) and after (Post) ischemia as indicated. D, Lactate dehydrogenase (LDH) activity of hearts treated with 1 lmol/L of
scrambled (AID(S)-TAT) or active (AID-TAT) peptides before (Pre) and after (Post) ischemia as indicated. E, GSH/GSSG ratio of hearts treated
with 1 or 10 lmol/L of scrambled (AID(S)-TAT) or active (AID-TAT) peptides before (Pre) and after (Post) ischemia as indicated. n represents
number of hearts. Statistical significance was determined using the Kruskal-Wallis test followed by Dunn’s multiple comparison test. AID
indicates alpha-interacting domain; GSH/GSSG, glutathione to oxidized glutathione; TAT, transactivator of transcription.
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AID-TAT Peptide Improves Developed Pressure in
Hearts Ex Vivo
We examined the effect of AID-TAT peptide on contractility ex
vivo in hearts exposed to ischemia then reperfusion. In hearts
exposed to scrambled peptide, developed pressure decreased
during reperfusion and did not improve during the 30 minutes
after ischemia (Figure 2A and 2B). Application of 1 lmol/L of
AID-TAT had no effect on postischemia recovery; however,
10 lmol/L of AID-TAT significantly improved developed
pressure 20 to 30 minutes after ischemia (Figure 2D and
2E). Application of 10 lmol/L of AID-TAT peptide did not alter
developed pressure over 60 minutes in the absence of I/R
(Figure 2E).
A B
C
E
D
Figure 2. AID-TAT peptide improves developed pressure in hearts ex vivo. A through D, Left ventricular
developed pressure (LVDevP) traces over time (compressed) of ex vivo hearts treated with 1 (A) or
10 lmol/L (B) of scrambled (AID(S)-TAT) peptide or 1 (C) or 10 lmol/L (D) of active (AID-TAT) peptide
before ischemia-reperfusion (Pre I/R) and after (Post I/R) as indicated. E, MeanSEM of LVDevP for all
hearts treated with 1 or 10 lmol/L of AID(S)-TAT or AID-TAT peptide as indicated (n represents number of
hearts). Statistical significance was determined using the Kruskal-Wallis test followed by Dunn’s multiple
comparison test. AID indicates alpha-interacting domain; TAT, transactivator of transcription.
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Effect of AID-TAT Peptide on Calcium Influx In
Vitro
Because AID-TAT peptide slows the inactivation rate of ICa-L
current,19,20 we examined the effect of the peptide on
changes in [Ca2+]i after activation of the channel. We and
others have shown previously that application of H2O2 can
directly increase ICa-L current.
4,10,11 As little as 5 minutes of
exposure to 30 to 50 lmol/L of H2O2 can cause further
release of superoxide from the mitochondria without inducing
apoptosis or necrosis and is sufficient to increase protein
synthesis, consistent with the development of myocyte
hypertrophy.10,12 ROS-induced ROS-release is proposed to
occur during reperfusion and can lead to mitochondrial
permeability transition pore opening and arrhythmia.27–29 We
mimicked the OS associated with reperfusion by applying
40 lmol/L of H2O2 to ventricular myocytes for 5 minutes,
followed by 10 U/mL of CAT to degrade the H2O2. Consistent
with previous studies,10 addition of H2O2 resulted in a small,
but significant, increase in [Ca2+]i assessed as changes in
Fura-2 that could be attenuated with addition of the ICa-L
antagonist, nisoldipine (Figure 3A and 3B). Application of
1 lmol/L of AID-TAT peptide had no effect on the increase in
Fura-2 signal induced by 40 lmol/L of H2O2. However, the
addition of 10 lmol/L of AID-TAT peptide attenuated the
increase in Fura-2 signal induced by H2O2 by 75%
(Figure 3C and 3D). Application of AID-TAT peptide did not
alter basal Fura-2 signal, indicating that the peptide did not
prevent calcium influx through the alpha subunit of the
channel (Figure 3D, inset right). These data suggest that
10 lmol/L, but not 1 lmol/L, of AID-TAT peptide can alter
ICa-L-activated calcium influx in myocytes.
Effect of AID-TAT Peptide on Cellular Superoxide
In Vitro
We have shown previously that 5 minutes of exposure of
myocytes to H2O2 results in a significant further increase in
superoxide assessed as changes in dihydroethidium (DHE)
fluorescence in guinea pig ventricular myocytes.10,30 The
further increase in superoxide occurred as a result of
increased calcium uptake into mitochondria, increased reduc-
tion of NAD+, and increased electron flow into mitochondrial
complex II.30 We assessed the effect of AID-TAT peptide on
DHE fluorescence in ventricular myocytes from C57BL mice.
Application of 40 lmol/L of H2O2 resulted in 70.325.1%
further increase in DHE signal that was completely attenuated
with nisoldipine (Figure 4A and 4B). Application of the
superoxide scavenger, N-tert-butyl-a-phenyl-nitrone (PBN),
completely abolished DHE signal, confirming specificity of
the indicator for superoxide (Figure 4B, inset right). Applica-
tion of 1 lmol/L of AID-TAT peptide had no effect on the
H2O2-induced increase in DHE signal, but 10 lmol/L of AID-
TAT peptide significantly attenuated the increase in DHE
signal (Figure 4C and 4D). AID-TAT peptide had no effect on
the DHE signal in the absence of H2O2, indicating that basal
production of superoxide was unaffected by the peptide
(Figure 4D, inset right).
Effect of AID-TAT Peptide on Reduction of NAD+
to NADH In Vitro
We assessed changes in mitochondrial NADH as autofluores-
cence in myocytes. Consistent with previous results,19
addition of H2O2 significantly increased NADH signal that
could be attenuated with nisoldipine (Figure 5A and 5B).
Collapse of the signal with addition of NaCN indicated that the
signal was mitochondrial in origin. Application of 1 and
10 lmol/L of AID-TAT peptide attenuated the increase in
NADH associated with application of H2O2 (Figure 5C and
5D). This suggested that AID-TAT peptide was altering NADH
as a result of effects on MMP or oxygen consumption.
Effect of AID-TAT Peptide onΨm and Flavoprotein
Oxidation In Vitro
We assessed effects of the peptide on Ψm assessed as
changes in JC-1 fluorescence. Consistent with previous
work,10,19,30 application of H2O2 increased JC-1 signal and
the response could be attenuated with nisoldipine (Fig-
ure 6A and 6B). Collapse of the signal with application of
NaCN demonstrated that the signal was mitochondrial in
origin. Application of 10 lmol/L of AID-TAT peptide signif-
icantly decreased the signal induced by H2O2 (Figure 6C and
6D). Addition of H2O2 to myocytes also increased flavopro-
tein oxidation measured as flavoprotein autofluorescence
(Figure 7A and 7B). An increase in flavoprotein autofluores-
cence is indicative of an increase in flavoprotein oxidation in
myocytes. It is also a measure of oxygen consumption in
myocytes. The response is dependent on Ψm, and addition
of the cyanide derivative, carbonyl cyanide-4-(trifluorometh-
oxy)phenylhydrazone (FCCP), significantly increased flavo-
protein signal (Figure 7A through 7C).25 Application of
10 lmol/L of AID-TAT significantly decreased flavoprotein
fluorescence, indicating that the peptide decreased flavo-
protein oxidation induced by H2O2 (Figure 7C and 7D).
Consistent with this result, we have previously demonstrated
that application of 1 lmol/L of AID-TAT peptide decreased
the formation of formazan from tetrozolium salt in guinea
pig ventricular myocytes induced by activation of the
channel with the dihydropyridine agonist, BayK(–) (Fig-
ure 7E).19 This is a measure of oxygen consumption,
suggesting that the peptide can decrease metabolic activity
in myocytes.
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AID-TAT Peptide Decreases Infarct Size and
Supports Contractility In Vivo
Rats underwent coronary artery ligation, and within 5 minutes
after commencement of reperfusion, 1 or 10 lmol/L of AID-
TAT peptide or AID(S)-TAT peptide was injected into the LV.
The chest was closed, and rats were allowed to recover for up
to 12 weeks. In a group of rats, saline was injected instead of
peptide (“saline”), and in another group of rats, the chest was
opened and closed without undergoing cardiac surgery and
rats were allowed to recover (“sham”). Before sacrifice,
ventricular function (LVPs and dP/dT) was assessed after
A B
C D
Figure 3. Effect of AID-TAT peptide on calcium influx in vitro. A, Representative traces of ratiometric Fura-2 fluorescence recorded in a
myocyte before and after 5 minutes of exposure to 40 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase and a
myocyte before and after 5 minutes of exposure to 0 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase. Vertical
arrows indicate when drugs were added. B, MeanSEM of changes in ratiometric Fura-2 fluorescence for all myocytes exposed to 40 lmol/L of
H2O2, 10 U/mL of catalase, and 10 lmol/L of nisoldipine (Nisol) as indicated. C, Representative traces of ratiometric Fura-2 fluorescence
recorded in myocytes before and after 5 minutes of exposure to 40 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase
in the presence of either 1 or 10 lmol/L of AID(S)-TAT or AID-TAT peptide as indicated. Vertical arrows indicate when drugs were added. D,
MeanSEM of changes in ratiometric Fura-2 fluorescence for all myocytes exposed to 40 lmol/L of H2O2, 10 U/mL of catalase, 1 or
10 lmol/L of AID(S)-TAT or AID-TAT peptide, and 10 lmol/L of nisoldipine (Nisol) as indicated. Statistical significance was determined using
the Kruskal-Wallis test followed by Dunn’s multiple comparison test. Inset above: meanSEM of changes in ratiometric Fura-2 fluorescence for
myocytes before and 30 and 60 minutes after exposure to 10 lmol/L of AID-TAT peptide as indicated. AID indicates alpha-interacting domain;
TAT, transactivator of transcription.
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catheterization of the LV. At the time of sacrifice, hearts were
excised and weighed and infarct size was assessed. Consis-
tent with our ex vivo data, rats treated with 1 or 10 lmol/L of
AID-TAT peptide had significantly smaller infarcts than rats
treated with AID(S)-TAT peptide (Figure 8A and 8B). This was
evident at 6 and 12 weeks after CAL (Figure 8B). At
12 weeks, heart/body weight ratios were larger in rats
treated with AID(S)-TAT, compared to rats treated with
A B
C D
Figure 4. Effect of AID-TAT peptide on cellular superoxide in vitro. A, Representative traces of DHE recorded in a myocyte before and after
5 minutes exposure to 40 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase and a myocyte before and after
5 minutes of exposure to 0 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase. Vertical arrows indicate when drugs
were added. B, MeanSEM of changes in DHE for all myocytes exposed to 40 lmol/L of H2O2, 10 U/mL of catalase, and 10 lmol/L of
nisoldipine (Nisol) as indicated. Inset above: the superoxide scavenger, N-tert-butyl-a-phenyl-nitrone (PBN), caused a 93.61.9% decrease in the
rate of DHE signal. C, Representative traces of DHE recorded in myocytes before and after 5 minutes of exposure to 40 lmol/L of H2O2
followed by 5 minutes of exposure to 10 U/mL of catalase in the presence of either 1 or 10 lmol/L of AID(S)-TAT or AID-TAT peptide as
indicated. Vertical arrow indicates when drugs were added. D, MeanSEM of changes in DHE for all myocytes exposed to 40 lmol/L of H2O2,
10 U/mL of catalase, 1 or 10 lmol/L of AID(S)-TAT or AID-TAT peptide, and 10 lmol/L of nisoldipine (Nisol) as indicated. Inset above:
MeanSEM of changes in DHE for myocytes before and 30 and 60 minutes after exposure to 10 lmol/L of AID-TAT peptide as indicated.
Statistical significance was determined using the Kruskal-Wallis test followed by Dunn’s multiple comparison test. AID indicates alpha-
interacting domain; DHE, dihydroethidium; TAT, transactivator of transcription.
DOI: 10.1161/JAHA.114.000961 Journal of the American Heart Association 9
AID-TAT Decreases Myocardial Injury Viola et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
AID-TAT peptide (Figure 8C). More important, left ventricle
systolic pressure LVSP (Figure 8D) and max dP/dT (Fig-
ure 8E) were significantly improved at 12 weeks post-CAL in
rats treated with 10 lmol/L of AID-TAT peptide. Because the
AID-TAT peptide also binds the smooth muscle isoform of ICa-L,
we tested whether the peptide acutely altered arterial blood
pressure in rats. After dual catheterization of the femoral
artery and LV, rats were injected intravenously with 1 lmol/L
A B
C D
Figure 5. Effect of AID-TAT peptide on reduction of NAD+ to NADH in vitro. A, Representative traces of NADH autofluorescence recorded in a
myocyte before and after 5 minutes of exposure to 40 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase and a
myocyte before and after 5 minutes of exposure to 0 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase. Vertical
arrows indicate when drugs were added. NADH fluorescence decreased after addition of 4 mmol/L of sodium cyanide (NaCN), consistent with
depletion of NADH after collapse of Ψm. B, MeanSEM of changes in NADH autofluorescence for all myocytes exposed to 40 lmol/L of H2O2,
10 U/mL of catalase, and 10 lmol/L of nisoldipine (Nisol) as indicated. C, Representative traces of NADH autofluorescence recorded in
myocytes before and after 5 minutes of exposure to 40 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase in the
presence of either 1 or 10 lmol/L of AID(S)-TAT or AID-TAT peptide as indicated. Vertical arrows indicate when drugs were added. NADH
fluorescence decreased after addition of 4 mmol/L of NaCN, consistent with depletion of NADH after collapse of Ψm. D, MeanSEM of changes
in NADH autofluorescence for all myocytes exposed to 40 lmol/L of H2O2, 10 U/mL of catalase, and 1 or 10 lmol/L of AID(S)-TAT or AID-TAT
peptide as indicated. Statistical significance was determined using the Kruskal-Wallis test followed by Dunn’s multiple comparison test. AID
indicates alpha-interacting domain; NAD+, nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine dinucleotide; TAT,
transactivator of transcription.
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of AID-TAT. Both the arterial and LV blood pressures were
recorded over 30 minutes. After 30 minutes, 10 lmol/L of
AID-TAT was injected and both pressures were recorded for a
further 60 minutes. No change in arterial pressure was
observed in the rats (Figure 8F).
Discussion
In the heart, L-type calcium channels are composed of the ion-
conducting and pore-forming Cav1.2 subunit that associates
with auxiliary subunits, including b2, a2d, and c subunits. The b2
A B
C D
Figure 6. Effect of AID-TAT peptide on Ψm in vitro. A, Representative traces of ratiometric JC-1 fluorescence recorded in a myocyte before and
after 5 minutes of exposure to 40 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase and a myocyte before and after
5 minutes of exposure to 0 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase. Vertical arrows indicate when drugs
were added. Sodium cyanide (NaCN; 4 mmol/L) was added to collapse Ψm as indicated. B, MeanSEM of changes in ratiometric JC-1
fluorescence for all myocytes exposed to 40 lmol/L of H2O2, 10 U/mL of catalase, and 10 lmol/L of nisoldipine (Nisol) as indicated. C,
Representative traces of ratiometric JC-1 fluorescence recorded in myocytes before and after 5 minutes of exposure to 40 lmol/L of H2O2
followed by 5 minutes of exposure to 10 U/mL of catalase in the presence of either 1 or 10 lmol/L of AID(S)-TAT or AID-TAT peptide as
indicated. Vertical arrows indicate when drugs were added. NaCN (4 mmol/L) was added to collapse Ψm as indicated. D, MeanSEM of
changes in ratiometric JC-1 fluorescence for all myocytes exposed to 40 lmol/L of H2O2, 10 U/mL of catalase, 1 or 10 lmol/L of AID(S)-TAT
or AID-TAT peptide, and 10 lmol/L of nisoldipine (Nisol) as indicated. Statistical significance was determined using the Kruskal-Wallis test
followed by Dunn’s multiple comparison test. AID indicates alpha-interacting domain; TAT, transactivator of transcription.
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Figure 7. Effect of AID-TAT peptide on flavoprotein oxidation in vitro. A, Representative traces of
flavoprotein autofluorescence recorded in a myocyte before and after 5 minutes of exposure to 40 lmol/
L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase and a myocyte before and after
5 minutes of exposure to 0 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase.
Vertical arrows indicate when drugs were added. Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
(FCCP; 10 lmol/L) was added to increase flavoprotein signal, confirming the signal was mitochondrial in
origin. B, MeanSEM of changes flavoprotein autofluorescence for all myocytes exposed to 40 lmol/L of
H2O2, 10 U/mL of catalase, 10 lmol/L of nisoldipine (Nisol), and 10 lmol/L of FCCP as indicated. C,
Representative traces of flavoprotein autofluorescence recorded in myocytes before and after 5 minutes
of exposure to 40 lmol/L of H2O2 followed by 5 minutes of exposure to 10 U/mL of catalase in the
presence of either 1 or 10 lmol/L of AID(S)-TAT or AID-TAT peptide derived against the AID of the L-type
calcium channel as indicated. Vertical arrows indicate when drugs were added. FCCP (10 lmol/L) was
added to increase flavoprotein signal, confirming the signal was mitochondrial in origin. D, MeanSEM of
changes in flavoprotein autofluorescence for all myocytes exposed to 40 lmol/L of H2O2, 10 U/mL of
catalase, 1 or 10 lmol/L of AID(S)-TAT or AID-TAT peptide, and 10 lmol/L of nisoldipine (Nisol) as
indicated. Statistical significance was determined using the Kruskal-Wallis test followed by Dunn’s
multiple comparison test. E, Exposure of guinea pig myocytes to BayK(–) causes a significant increase in
formation of formazan from tetrozolium salt that can be attenuated by nisoldipine and by AID-TAT
peptide.19 AID indicates alpha-interacting domain; TAT, transactivator of transcription.
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Figure 8. AID-TAT peptide decreases infarct size and supports contractility in vivo. A, Representative sections from rat
hearts treated with 1 lmol/L of scrambled (AID(S)-TAT) or active (AID-TAT) peptides. Infarct size is assessed as area that did
not take up nitroblue tetrazolium dye. B, MeanSEM of infarct size in hearts following myocardial infarction expressed as a
percentage (%) of total left ventricular (LV) area for all hearts treated with 1 or 10 lmol/L of AID(S)-TAT or AID-TAT peptide as
indicated. C, MeanSEM of heart/body weight ratio (Hwt/Bwt) for all hearts treated with 10 lmol/L of AID(S)-TAT or AID-TAT
peptide as indicated. D, MeanSEM of left ventricular systolic pressure (LVSP) for all hearts treated with 10 lmol/L of AID(S)-
TAT or AID-TAT peptide as indicated. E, MeanSEM of maximum dP/dt for all hearts treated with 10 lmol/L of AID(S)-TAT or
AID-TAT peptide as indicated. F, MeanSEM of systolic and diastolic arterial blood pressure (BP) for all animals treated with 1
or 10 lmol/L of AID-TAT peptide as indicated. n represents number of animals. AID indicates alpha-interacting domain; TAT,
transactivator of transcription.
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auxiliary subunit is an effective modulator of channel inactiva-
tion and open probability.31–33 The discovery of a sequence
motif in the I-II loop of the Cav1.2 alpha-interacting domain
revealed the contact point for the auxiliary b2 subunit.
34 The
motif is highly conserved in all a1 subunits. Therefore, a peptide
was synthesized that interfereswith the binding of theb subunit
to the I-II linker of the a1C subunit with the purpose of studying
the biophysical modulation of the currents through the a
subunit by the b subunit.20 We and others have demonstrated
that application of the AID peptide slows the inactivation rate of
the L-type calcium current and decreases open probability of
single-channel currents.19,20,22 In addition, the b subunits
of voltage-dependent calcium channels are members of the
membrane-associated guanylate kinase family of proteins that
are known scaffolding proteins with a type-3 Sarc homology
domain and a guanylate kinase domain.35,36 It is currently
recognized that a number of structural proteins directly interact
with the b subunit, including members of the Gem/Kir family
and the large subsarcolemmal structural protein, AHNAK.37
Therefore, it is reasonable to argue that the b subunit of the
channel can modulate calcium-current activation and inactiva-
tion kinetics, in addition to influencing structural proteins that it
associates with.
We have found that activation of ICa-L can modulate
mitochondrial function. This occurs as a result of increased
calcium influx and influences NADH production, superoxide
production, and metabolic activity.19 We also found that
activation of the channel caused an increase in MMP. This
was mediated through the movement of cytoskeletal proteins
because depolymerization of F-actin filaments or application
of AID-TAT peptide (that immobilises the b subunit and
induces functional uncoupling from F-actin) attenuated the
response.19 Because I/R injury is associated with an increase
in metabolic activity and OS, we hypothesized, in this study,
that application of AID-TAT peptide can alter I/R injury by an
effect on mitochondrial function. We demonstrate that
application of 1 lmol/L of AID-TAT can decrease infarct size
in guinea pig hearts exposed to I/R ex vivo and in rats that
had undergone CAL in vivo (Figures 1 and 8). Application of
AID-TAT peptide decreased mitochondrial NADH production
(Figure 5), MMP (Figure 6), flavoprotein oxidation, and met-
abolic activity (Figure 7) induced by application of H2O2. This
occurred in a concentration-dependent manner because
10 lmol/L of AID-TAT induced larger responses. Application
of AID-TAT peptide also attenuated the increase in Fura-2
signal (Figure 3) and superoxide production (Figure 4)
induced by H2O2. Upon binding of the peptide, the b-AID
complex dissociates from the a subunit, resulting in rapid
removal.20 Because the turnover rate of the channel complex
in vivo is 96 hours,38 we can presume that the duration of
the loss of b subunits after a single injection of the peptide
will be 3 to 4 days after infarction.
We demonstrate that heart/body weight ratio does not
increase and contractility is supported for up to 12 weeks in
rats injected with 10 lmol/L of AID-TAT that had undergone
CAL in vivo. Contractility appears to normalize early after
administration of the peptide, as evidenced by an improve-
ment in developed pressure within 30 minutes after ischemia
in hearts that had undergone I/R injury ex vivo (Figure 2). We
propose that the improvement in contractile function occurs
as a result of a decrease in OS and metabolic activity in the
hearts. Alterations in [Ca2+]i after application of AID-TAT were
not deleterious because intravenous injection of the peptide
did not alter arterial pressure during continuous recordings in
rats in vivo (Figure 8F) or in hearts perfused with the peptide
ex vivo in the absence of I/R (Figure 2E).
The sequence motif in the I-II loop of the Cav1.2 is highly
conserved across species. In this study, we have demon-
strated a beneficial effect of the peptide in guinea pig heart,
mouse myocytes, and rats. The reduction in infarct size and
improvement in contractility after administration of the
peptide could provide significant benefits post-MI in the
human heart.
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